Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pediatric Open-Label Extension Study

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Amgen Identifier:
First received: August 31, 2005
Last updated: March 18, 2016
Last verified: March 2016
The purpose of this study is to evaluate the long-term safety and efficacy of etanercept in pediatric subjects with moderate to severe psoriasis.

Condition Intervention Phase
Pediatric Plaque Psoriasis
Drug: Etanercept
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects With Plaque Psoriasis

Resource links provided by NLM:

Further study details as provided by Amgen:

Primary Outcome Measures:
  • Subject incidence of adverse events, including infectious episodes, serious adverse events, and serious infectious episodes [ Time Frame: 168 Weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Injection site reactions [ Time Frame: 168 Weeks ] [ Designated as safety issue: Yes ]
  • exposure adjusted event rates for adverse events [ Time Frame: 168 Weeks ] [ Designated as safety issue: Yes ]
  • infections and injection site reactions [ Time Frame: 168 weeks ] [ Designated as safety issue: Yes ]
  • physical examination [ Time Frame: 168 weeks ] [ Designated as safety issue: No ]
  • vital signs [ Time Frame: 168 weeks ] [ Designated as safety issue: No ]
  • laboratory toxicities [ Time Frame: 168 weeks ] [ Designated as safety issue: Yes ]
  • anti-etanercept antibodies [ Time Frame: 168 weeks ] [ Designated as safety issue: Yes ]
  • PASI 50 [ Time Frame: 168 weeks ] [ Designated as safety issue: No ]
  • PASI 75 [ Time Frame: 168 weeks ] [ Designated as safety issue: No ]
  • PASI 90 [ Time Frame: 168 weeks ] [ Designated as safety issue: No ]
  • Clear or almost clear status of sPGA [ Time Frame: 168 weeks ] [ Designated as safety issue: No ]
  • percent improvement in CDLQI [ Time Frame: 168 Weeks ] [ Designated as safety issue: No ]
  • improvement from baseline in joint pain [ Time Frame: 168 weeks ] [ Designated as safety issue: No ]
  • Percent improvement in PASI score [ Time Frame: 168 weeks ] [ Designated as safety issue: No ]

Enrollment: 182
Study Start Date: August 2005
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Etanercept Drug: Etanercept
open-label at a dose of 0.8 mg/kg (up to an intended dose of 50 mg) given QW SC in 1 or 2 injections


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Inclusion Criteria: - Enrollment on previous Amgen study 20030211 Exclusion Criteria: - Serious or clinically significant adverse event on Amgen study 20030211 related to etanercept
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00141921

Sponsors and Collaborators
Study Director: MD Amgen
  More Information

Additional Information:
Responsible Party: Amgen Identifier: NCT00141921     History of Changes
Other Study ID Numbers: 20050111 
Study First Received: August 31, 2005
Last Updated: March 18, 2016
Health Authority: United States: Food and Drug Administration

Keywords provided by Amgen:
plaque psoriasis
clinical trial

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Gastrointestinal Agents
Immunosuppressive Agents
Immunologic Factors processed this record on December 09, 2016